Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDL NASDAQ:EQ NYSE:FRX TSE:ITH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.38-7.4%$1.36$0.77▼$2.63$114.09M1.05367,737 shs795,076 shsEQEquillium$0.71+81.6%$0.37$0.27▼$1.50$25.36M1.15576,012 shs143.57 million shsFRXForest Road Acquisition$10.30$9.72▼$18.20$450MN/A2.07 million shs40,482 shsITHInternational Tower Hill MinesC$1.56C$1.33C$0.57▼C$1.67C$219.02M1.1731,297 shs5,450 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics0.00%-4.17%-8.97%+21.05%-36.11%EQEquillium0.00%+76.31%+117.13%+69.05%-4.98%FRXForest Road Acquisition0.00%0.00%0.00%0.00%0.00%ITHInternational Tower Hill Mines0.00%+1.30%+32.20%+64.21%+155.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDLCardiol Therapeutics1.9407 of 5 stars3.74.00.00.00.00.00.6EQEquillium1.8009 of 5 stars3.24.00.00.00.61.70.0FRXForest Road AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AITHInternational Tower Hill MinesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 3.33Buy$8.00479.71% UpsideEQEquillium 2.33Hold$3.00322.54% UpsideFRXForest Road Acquisition 0.00N/AN/AN/AITHInternational Tower Hill Mines 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EQ, ITH, FRX, and CRDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.00(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.22 per shareN/AEQEquillium$41.10M0.62N/AN/A$0.54 per share1.31FRXForest Road AcquisitionN/AN/AN/AN/A$0.56 per shareN/AITHInternational Tower Hill MinesN/AN/AC$0.07 per share22.50C$0.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$26.77M-$0.34N/AN/AN/AN/A-209.63%-141.09%8/11/2025 (Estimated)EQEquillium-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)FRXForest Road Acquisition-$7.92MN/A0.00N/AN/AN/AN/AN/AN/AITHInternational Tower Hill Mines-C$2.36M-C$0.02N/A∞N/AN/A-5.82%-3.65%N/ALatest EQ, ITH, FRX, and CRDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025EQEquillium-$0.1850N/AN/AN/AN/AN/A8/11/2025Q2 2025CRDLCardiol Therapeutics-$0.11N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AFRXForest Road AcquisitionN/AN/AN/AN/AN/AITHInternational Tower Hill MinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.013.263.26EQEquilliumN/A2.702.70FRXForest Road AcquisitionN/A0.370.37ITHInternational Tower Hill MinesN/A10.3730.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%EQEquillium27.05%FRXForest Road AcquisitionN/AITHInternational Tower Hill Mines71.80%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%EQEquillium31.60%FRXForest Road AcquisitionN/AITHInternational Tower Hill Mines0.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics2082.68 million78.34 millionNot OptionableEQEquillium4035.72 million24.43 millionNot OptionableFRXForest Road AcquisitionN/A37.50 millionN/ANot OptionableITHInternational Tower Hill Mines220140.40 millionN/ANot OptionableEQ, ITH, FRX, and CRDL HeadlinesRecent News About These CompaniesInternational Tower Hill Mines (TSE:ITH) Trading Down 6.6% - What's Next?August 1 at 12:41 AM | marketbeat.comInternational Tower Hill Mines (TSE:ITH) Hits New 12-Month High - Here's WhyJuly 31 at 4:28 PM | marketbeat.comInternational Tower Hill Mines (TSE:ITH) Reaches New 1-Year High - Time to Buy?July 24, 2025 | marketbeat.comInternational Tower Hill Mines: Akin To NovaGold's Little BrotherJuly 15, 2025 | seekingalpha.comInternational Tower Hill Mines (TSE:ITH) Sets New 12-Month High - Here's What HappenedJuly 11, 2025 | marketbeat.comInternational Tower Hill Mines (TSE:ITH) Stock Crosses Above 50-Day Moving Average - What's Next?July 10, 2025 | marketbeat.comInternational Tower Hill Mines Ltd. (THM) - Yahoo FinanceJune 27, 2025 | nz.finance.yahoo.comInternational Tower Hill Mines Files 2025 First Quarter Financial ResultsMay 9, 2025 | finance.yahoo.comInternational Tower Hill Mines Ltd. (THM): Among Billionaire John Paulson’s Stocks with Huge Upside PotentialMay 7, 2025 | uk.finance.yahoo.comTrump signs order seeking to jump-start mining of the ocean floorApril 25, 2025 | msn.comInternational mining giant dropping out of partnership in Alaska gold mining projectApril 24, 2025 | alaskabeacon.comAWhy International Tower Hill Mines Ltd.’s (THM) Stock Is Up 8.29%April 11, 2025 | aaii.comAInternational Tower Hill Mines Approves 2025 Livengood Gold Project Work Plan and Files 2024 Year End Financial ResultsMarch 12, 2025 | ca.finance.yahoo.comInternational Tower Hill Mines announces $3.9M non-brokered private placementMarch 4, 2025 | markets.businessinsider.com7 Most Obscure Towns In America You Wouldn't Think To VisitNovember 7, 2024 | msn.comHedge funds investors control 32% of International Tower Hill Mines Ltd. (TSE:ITH) and were rewarded last week after stock increased 44%October 17, 2024 | finance.yahoo.comJust Over the Border from Israel, a Hezbollah Cache of Explosives and MinesOctober 14, 2024 | nytimes.comPrince Harry Is Keeping Princess Diana's Landmine Legacy Alive: 'He Wants to Finish the Job' (Exclusive)September 29, 2024 | people.comPDozens of Massachusetts lawmakers tell RMV to hit the brakes on revoking CDLsSeptember 27, 2024 | ca.news.yahoo.comAfter personal appeal from Zelensky, Trump agrees to meet with the Ukrainian president after allSeptember 27, 2024 | washingtonexaminer.comW8 Theme Parks That Go All Out for Halloween and ChristmasSeptember 25, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonPalantir’s Revenue Surge to $1B: Growth vs. ValuationBy Chris Markoch | July 9, 2025View Palantir’s Revenue Surge to $1B: Growth vs. ValuationThese 3 Rare Earth Stocks Are Surging Alongside MP MaterialsBy Leo Miller | July 19, 2025View These 3 Rare Earth Stocks Are Surging Alongside MP MaterialsJoby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?By Jeffrey Neal Johnson | July 14, 2025View Joby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?5 Stocks to Buy and Hold for the Rise of Physical AIBy Thomas Hughes | July 23, 2025View 5 Stocks to Buy and Hold for the Rise of Physical AIEQ, ITH, FRX, and CRDL Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.38 -0.11 (-7.38%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.40 +0.02 (+1.45%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Equillium NASDAQ:EQ$0.71 +0.32 (+81.59%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.57 -0.14 (-19.01%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Forest Road Acquisition NYSE:FRXForest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.International Tower Hill Mines TSE:ITHC$1.56 0.00 (0.00%) As of 08/1/2025 03:59 PM EasternInternational Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an advanced stage exploration project namely the Livengood Gold Project. It is located approximately 70 miles northwest of Fairbanks, Alaska in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska mental health trust, a number of smaller private mineral leases, Alaska state mining claims purchased or located by the company and patented ground held by the company. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
